Literature DB >> 3871706

Regulation of human granulocyte function by products derived from murine tumors.

M A Vadas, I Clark-Lewis.   

Abstract

Murine EL-4 thymoma was found to produce a factor that activated antibody-dependent cell-mediated cytotoxicity by human eosinophils and neutrophils. The eosinophil-activating factor had some properties similar to human eosinophil colony-stimulating factor in being heat stable, inactivated by 2-mercaptoethanol, and cochromatographing by gel filtration with a factor that promoted the growth of pure eosinophil colonies from human bone marrow. The neutrophil-activating factor from EL-4 was also heat stable but was not inactivated by 2-mercaptoethanol and was found in two peaks on chromatography, neither having human neutrophil-CSF activity but one cochromatographing with mouse granulocyte-macrophage CSF. EL-4 therefore secretes factors that activate two types of human granulocytes. Several other murine thymomas and macrophage cell lines produced a neutrophil-activating factor, the production of which could not be correlated with that of several other known lymphokines. Murine tumors produce factors that activate human granulocytes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871706

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  4 in total

Review 1.  Eosinophils. Assays and interpretation.

Authors:  D E Maddox
Journal:  Clin Rev Allergy       Date:  1988

2.  Giant eosinophil colonies from cultures of bone marrow cells.

Authors:  J H Butterfield; D Weiler
Journal:  In Vitro Cell Dev Biol       Date:  1986-03

3.  Eosinophil differentiating activity in sera of patients with AIDS under recombinant IL-2 substitution.

Authors:  P Kern; M Dietrich
Journal:  Blut       Date:  1986-04

4.  Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells.

Authors:  A F Lopez; C G Begley; D J Williamson; D J Warren; M A Vadas; C J Sanderson
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.